TP Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$144.4M
Industry:Biotech
Founded:2013
Lead Investor(s):Foresite Capital, VenBio Partners
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • TP Therapeutics's estimated revenue is currently $11.8M per year.
  • TP Therapeutics received $80.0M in venture funding in October 2018.
  • TP Therapeutics's estimated revenue per employee is $145432
  • TP Therapeutics's total funding is $144.4M.

Employee Data

  • TP Therapeutics has 81 Employees.
  • TP Therapeutics grew their employee count by 145% last year.
  • TP Therapeutics currently has 15 job openings.

Executive Contacts

NameTitle
Miriam CruzVice President Clinical Operations, Oncology
Dayong ZhaiDirector, Biology
Yuelie LuVice President, CMC Operations
Jessica CraneDirector Clinical Operations
Robert XinSVP, Clinical Development
John HuangExecutive Director of Translational Research
Armin GraberVice President Of Companion Diagnostics & Biomarkers
Susan MartinExecutive Assistant To Chief Executive Officer
Denise LeoneDirector, Biostatistics and Programming
Junming ZhuSr. Director of Biostatistics and Data Management

What Is TP Therapeutics?

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. Our lead therapeutic project, TPX-0005, is in clinical development (TRIDENT-1). TP- Turning Point Medicines for Life!

keywords:Biotechnology,Healthcare,Pharmaceuticals

81

Number of Employees

$11.8M

Revenue (est)

15

Current Jobs

145%

Employee Growth %

$144.4M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%$53M
Mission Bio
$10.7M7445%
Rigel Pharmaceu...
$42M2904%
ProTrials Resea...
$26.4M1823%
Trace Genomics
$5.9M4137%
Advanced Cell D...
$25.7M1788%
CellMax Life
$5.7M4011%$9M
Vaxart
$4.2M33-15%$58.6M
Full Spectrum A...
$6M425%
Calysta
$7.1M49-2%

TP Therapeutics News

16/08/2019 - Roche undercuts price of Bayer cancer drug after winning ...

Roche has won US Food and Drug Administration (FDA) approval for its rival to Bayer's oncology drug Vitrakvi (larotrectinib). The approval ...

06/09/2019 - What Do Traders Know That We Don't?: Amicus Therapeutics ...

ATR of the company Amicus Therapeutics, Inc., stands at 0.46 while a Beta ... Target pricing (TP) at which a trader projects that a buyer will ...

06/09/2019 - Stock Performance Summary:: Sarepta Therapeutics, Inc. Gain ...

Sarepta Therapeutics, Inc., belongs to the Healthcare sector and ... Analyst's mean target price(TP) for the company is 210.45 while analysts ...

TP Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-01-10$1.4MUndisclosedArticle
2016-03-23$18.0MUndisclosedArticle
2017-05-24$45.0MCLilly Asia VenturesArticle
2018-10-22$80.0MUndisclosedForesite CapitalArticle

TP Therapeutics Executive Hires

DateNameTitleReference
2017-12-05Sheila GujrathiStrategic AdvisorArticle
2018-05-15Athena CountouriotisEVP/Chief Medical OfficerArticle
2018-10-22Athena CountouriotisCEOArticle
2019-01-29Robert XinSVP Clinical DevelopmentArticle
2019-03-26Jim MazzolaLead Corporate Communication and Investor RelationsArticle